指南与共识类风湿关节炎

合成与生物DMARDs安全性:EULAR 2019类风湿关节炎管理建议系统文献综述

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
指南 / 共识 · Ann Rheum Dis · 2020-02-07

OBJECTIVES: To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).…

要点

  • bDMARDs严重感染风险总体与csDMARDs无差异,但两项高偏倚风险研究显示风险增加。
  • 托珠单抗较csDMARDs和TNFi增加下消化道穿孔风险,JAK抑制剂可能增加VTE风险。
  • bDMARDs癌症风险与csDMARDs无显著增加,带状疱疹风险在bDMARDs间相似。

核心结论

  • 该SLR确认bDMARDs已知安全性特征,但JAK抑制剂相关VTE风险需进一步评估。

研究设计与样本

  • 系统文献综述纳入比较任何DMARD与另一干预措施安全结局的观察性研究,要求有对照组。
  • 对无登记数据的治疗(如sarilumab、baricitinib、upadacitinib)使用RCT和长期扩展研究。

主要发现

  • 9项研究显示bDMARDs间严重感染风险无差异,2项高偏倚风险研究显示bDMARDs较csDMARDs风险增加(调整发病率比3.1-3.9)。
  • 带状疱疹感染风险在bDMARDs间相似,但一项研究显示托法替尼较阿巴西普风险增加(调整HR 2.0)。
  • 5项研究显示bDMARDs较csDMARDs癌症风险未增加。
  • 托珠单抗较csDMARDs增加下消化道穿孔风险(aHR 4.5),较TNFi增加风险(aHR 2.6-4.0)。
  • RCT/LTE总体未发现意外安全结局,但JAK抑制剂可能增加静脉血栓栓塞风险。

关键数值与推荐

  • bDMARDs较csDMARDs严重感染调整发病率比3.1-3.9(高偏倚风险研究)。
  • 托法替尼较阿巴西普带状疱疹调整HR 2.0。
  • 托珠单抗较csDMARDs下消化道穿孔aHR 4.5,较TNFi aHR 2.6-4.0。

临床怎么用

  • 临床使用bDMARDs时应关注严重感染风险,尤其在高偏倚风险研究提示风险增加的情况下。
  • 使用托珠单抗需警惕下消化道穿孔风险,尤其相较csDMARDs和TNFi。
  • 使用JAK抑制剂时应评估静脉血栓栓塞风险,尤其对高风险患者。

局限性

  • 部分研究存在高偏倚风险,可能影响结果可靠性。
  • JAK抑制剂VTE风险证据尚不充分,需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To perform a systematic literature review (SLR) concerning the safety of synthetic (s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis (RA). METHODS: An SLR of observational studies comparing safety outcomes of any DMARD with another intervention for the management of RA. A comparator group was required for inclusion. For treatments still without registry data (eg, sarilumab and the Janus kinase (JAK) inhibitors baricitinib, upadacitinib), randomised controlled trials (RCTs) and long-term extensions (LTEs) were used. Risk of bias (RoB) was assessed according to standard procedures. RESULTS: Forty-two observational studies fulfilled the inclusion criteria, addressing safety outcomes with bDMARDs and sDMARDs. Nine studies showed no difference in the risk of serious infections across bDMARDs and two studies (high RoB) showed an increased risk with bDMARDs compared with conventional synthetic (cs) DMARDs (adjusted incidence rate ratio 3.1-3.9). The risk of Herpes zoster infection was similar across bDMARDs, but one study showed an increased risk with tofacitinib compared with abatacept (adjusted HR (aHR) 2.0). Five studies showed no increased risk of cancer for bDMARDs compared with csDMARDs. An increased risk of lower intestinal perforation was found for tocilizumab compared with csDMARDs (aHR 4.5) and tumour necrosis factor inhibitor (TNFi) (aHR 2.6-4.0). Sixty manuscripts reported safety data from RCTs/LTEs. Overall, no unexpected safety outcomes were found, except for the possibly increased risk of venous thromboembolism (VTE) with JAK inhibitors. CONCLUSION: Data obtained by this SLR confirm the known safety profile of bDMARDs. The risk of VTE in RA, especially in patients on JAK inhibitors, needs further evaluation.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 32033941. doi:10.1136/annrheumdis-2019-216653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。